Workshop The science and methodologies behind HTA, diversity and commonality across the EU

15
Workshop The science and methodologies behind HTA, diversity and commonality across the EU Achieving more patient centred HTA in different countries

description

Workshop The science and methodologies behind HTA, diversity and commonality across the EU. Achieving more patient centred HTA in different countries. Terminology. Patients Citizens Public Service users etc. Rationale for HTA. - PowerPoint PPT Presentation

Transcript of Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Page 1: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

WorkshopThe science and methodologies

behind HTA, diversity and commonality across the EU

Achieving more patient centred HTA in different countries

Page 2: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Terminology

• Patients

• Citizens

• Public

• Service users– etc

Page 3: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Rationale for HTA

• There are increasing expectations of what healthcare is available/provided

• Increasing demands on available budgets

• Decisions on what should be made available should be rational based on all available evidence

Page 4: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Health Technology Assessment (HTA)

• HTA is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner

Page 5: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Different types of HTA

• Assessment of available evidence to clarify the way a technology should be used

• Assessment of available evidence to determine whether there is enough evidence to support the use of a technology

• Assessment of available evidence of effectiveness and cost effectiveness to determine whether a technology offers value for money

Page 6: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Evidence used in HTA

• Clinical trials– Efficacy– Quality of life

• Economic evaluations

• Modelling

Page 7: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Clinical trials

• Get involved in the design of clinical trials so they measure what is important to patients

• Ensure trial populations are broadly relevant

• Help put the results of trials into the context of a patient’s life

Page 8: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Health related quality of life

• Help develop and test QOL tools so they reflect what matters to patients

• Try to ensure that disease specific tools are developed and validated– Reflect changes in priorities for patients at

different stages of illness

• Think about carers quality of life

Page 9: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Economic evaluations

• Cost– Incremental cost effectiveness ratio (ICER)– Cost utility analysis

• Cost per quality adjusted life year (QALY)

– Disability adjusted life year (DALY)

Page 10: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

How is patient evidence incorporated into HTA?

• Patient input to trials

• Patient input to assessment reports

• Patient evidence

• Reviewing recommendations

• Making recommendations available in plain language

Page 11: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Challenges of involving patients in research

• Challenges experienced by patients• Contribution hindered by difficulties with access

and communication• Relationship (doctor supremacy, fear of

preferential care)• Tokenism (political correctness)• Anxieties of new role – unclear about role and

ability to contribute, perceived value of contribution, not appearing foolish, lack of familiarity with technical terms

Hewlett et al, 2006

Page 12: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Patient evidence

• Quantitative– Questionnaires/surveys– Patient Organisation databases

• Qualitative– Individual interviews– Focus groups discussions and interviews– Futures workshops– Blogs, etc

Page 13: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

Patient perspective

• Use research that is

• – well planned and structured

• – systematic

• – reported clearly showing sources, methods, potential biases, assumptions and findings

Page 14: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

3 fundamental issues affecting theme

Page 15: Workshop The science and methodologies behind HTA, diversity and commonality across the EU

3 core recommendations